Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.

Marcelo V. Negrao,Vassiliki A. Papadimitrakopoulou, Andrew C. Price,Alda L. Tam,Muhammad Furqan,Sandeep T. Laroia,Erminia Massarelli,Jose Pacheco,John V. Heymach,Anne S. Tsao,Gary V. Walker, Lalit Vora,David Mauro,Heather Kelley,James E. Wooldridge,Arthur M. Krieg,Jiaxin Niu

JTO clinical and research reports（2023）

引用 0|浏览21

暂无评分

摘要

Vidutolimod and atezolizumab with and without RT had a manageable safety profile, with minimal clinical activity in heavily pretreated patients with programmed cell death protein 1 or programmed death-ligand 1 blockade-resistant NSCLC.

查看译文

关键词

Atezolizumab,NSCLC,Radiation,TLR9 agonist,Vidutolimod

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要